Chimeric Therapeutics Ltd FNN Investor Event Transcript
Chimeric Therapeutics is a clinical-stage cell therapy company. We were listed on the ASX in January of 2021, just over a year ago today. And at the time, we had one asset that we were developing in one disease area. Today, a short 12 months later, we now are developing seven assets across 10 different types of cancer, rapid growth in just 12 short months.
Our portfolio is diversified and innovative. We use first and best-in-class NK and T cell derived therapies that are both individualized, or autologous, and allogeneic or off-the-shelf. We have an extensive clinical development program where we have two current clinical trials. We are planning two IND submissions to the FDA for approval to start two more clinical trials in 2022. And by 2023, we plan to have eight clinical programs in place.
Recently, we've seen encouraging early signals in our lead asset, our chlorotoxin CAR T, promising early data in recurrent/progressive glioblastoma patients, one of the most fatal brain cancers that exists. And we are doing all this with a team
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
